Abstract:Abstract Background Peritoneal dissemination (PD) is a type of metastasis frequently found in gastrointestinal (GI) cancer patients, resulting in the production of massive malignant ascites which associate with poor prognosis. However, the question of how the expression of tumor biomarkers on cancer cells in malignant ascites correlates with PD is yet to be answered. This study aims to investigate the clinical significance of PD-L1 and HER2 expression on malignant ascites disseminated tumor cells (maDTCs) in GI carcinoma patients. Patients and Methods Paired blood and malignant ascites specimens were respectively collected from 24 of metastatic GI subjects, including 15 gastric, 2 pancreatic, 1 esophageal, and 6 colorectal cancer patients. Non-hematologic CTCs and maDTCs were enriched by subtraction enrichment (SE), followed by immunostaining-FISH (iFISH) to co-examine PD-L1 and HER2 expression on aneuploid maDTCs and CTCs. In addition, CD4+, CD8+, Treg and naive T cells in the same cohort of samples were quantified by flow cytometry. Results In situ karyotypic and phenotypic characterization performed by iFISH showed that the average number of maDTCs in the 24 patients was 32755/ml ascites, which was significantly higher than the average number of CTCs detected (3.5/ml blood) (P<0.0001). The number of maDTCs and CTCs exhibited no correlation between each other (Pearson's product-moment correlation coefficient, R=-0.03, P=0.89). Further examination indicated that PD-L1 was expressed on 50% of maDTCs compared to only 11% for CTCs (P=0.0002). No correlation of PD-L1 expression between maDTCs and CTCs was observed (Pearson's product-moment correlation coefficient, R=0.25, P=0.24). Co-expression of PD-L1 and HER2 on CTCs and maDTCs was respectively examined in the recruited 15 gastric cancer (GA) patients. All 15 patients were histopathological HER2 negative (hHER2-). One subject (1/15=6.7%) showed 1 double HER2+/PD-L1+ CTC (1/63 CTCs in 15 GA patients=1.6%). In comparison, 6 patients (6/15=40%) had a total of 290377 HER2+/PD-L1+ maDTCs detected (290377/1306783 overall maDTCs=22%). In addition, flow cytometry analyses revealed that 5% of lymphocytes in malignant ascites were immunosuppression relevant regulatory T cells (Tregs), compared to only 2% of Tregs identified in the paired peripheral blood sample of the same patient. Conclusions Our study suggested that a higher proportion of Tregs in malignant ascites may contribute towards fostering an immunosuppressive microenvironment.PD-L1+/HER2+ maDTCs, in such an immunosuppressive microenvironment, might be able to evade immune system attack. Moreover, PD-L1 and HER2 identified on maDTCs could serve as therapy targets with respect to inhibition of peritoneal metastasis, potentially leading to an additional treatment strategy for GI cancer patients with malignant ascites. Citation Format: Yang Chen, Changsong Qi, JiaJia Yuan, Dan Liu, Zhi Peng, Xiaotian Zhang, Jian Li, Pin Peter Lin, Yilin Li, Lin Shen. Elevated PD-L1 and HER2 expression on aneuploid carcinoma cells in malignant ascites accelerate stumor cell immune evasion in gastrointestinal cancer patients [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5381.

The study of obtained cellular MDR1expression and apoptosis of mouse ascites S180 cell and its peripheral lymphocytestimulated by chemotherapy

Mechanism Study of Doxorubicin-schisandrin B Co-delivery Liposomes to Overcome Multidrug Resistance

Effect of bevacizumab on angiogenesis and related cytokines in mice with malignant pleural effusion

First-line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients.

The Relationship Between Mismatch Repair (MMR) Proteins Status and the Response to Conventional Neoadjuvant Therapy in Colorectal Cancer (CRC).

Effect of RRM1 and BRCA1 Expressions on Efficiency of Gemcitabine and Platinum in Patients with Advanced Non-Small Cell Lung Cancer

The Correlation Between the Expression of Multidruc Resistance Related Gene and Cell Apoptosis and Clinical Significance in Non-Small Cell Lung Cancer

Effect of Arsenic Trisulfide on Survival of Mice Bearing Acute Promyelocytic Leukemia Ascites

Ddifferent expression of multidrug-resistance and apoptosis related genes in human lung adenocarcinoma parental cell line A549 and cisplatin-resistant cell line A549DDP

Cmar_a_196450 2449..2456

RRM1 Mrna Expression Levels in Malignant Pleural and Peritoneal Effusions Are Associated with Chemosensitivity to Gemcitabine in Vitro

Late pulmonary valve replacement after repair of tetralogy of Fallot.

New Mouse Xenograft Model Modulated by Tumor-Associated Fibroblasts for Human Multi-Drug Resistance in Cancer

Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis

Abstract 5381: Elevated PD-L1 and HER2 expression on aneuploid carcinoma cells in malignant ascites accelerate stumor cell immune evasion in gastrointestinal cancer patients

Expressions of bcl-2,p16 and nm23 genes in tumors of mice induced by Staphylococcus aureus L-form

Enhanced Sensitivity to Mitomycin C by Abating Heat Shock Protein 70 Expression in Human Bladder Cancer Cell Line of BIU-87.

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers

Experimental Study on Target Intervention of Mesenchymal Stem Cells in Patients with Multiple Myeloma with As2O3

Establishment of nude mice model with human hepatocellular carcinoma multidrug resistance exeografts

Effect of Cisplatin on the Frequency and Immuno-inhibitory Function of Myeloid-derived Suppressor Cells in A375 Melanoma Model.